Table 1.
The clinical features of patients with PAH secondary to CHD.
| Reversible PAH group (n = 38) | Irreversible PAH group (n = 22) | P value | |
|---|---|---|---|
| Age (years) (mean ± SD) | 22.5 ± 8.7 | 29.0 ± 5.7 | <0.05 |
| Sex (M/F) | 17/21 | 9/13 | >0.05 |
| Diagnosis (VSD/ASD) | 17/21 | 14/8 | >0.05 |
| Resting SpO2 (%) (mean ± SD) | 97.6 ± 1.44 | 96.0 ± 1.0 | >0.05 |
| Post-exercise SpO2 (%) (mean ± SD) | 97.1 ± 1.4 | 95.4 ± 1.0 | >0.05 |
| MAP (mmHg) (mean ± SD) | 79.1 ± 3.5 | 80.7 ± 3.3 | >0.05 |
| mPAP (mmHg) (mean ± SD) | 65.8 ± 7.4 | 70.8 ± 6.2 | >0.05 |
| mPAP/MAP (mean ± SD) | 0.83 ± 0.09 | 0.87 ± 0.07 | >0.05 |
| PVRi (Wood unit) (mean ± SD) | 7.6 ± 1.6 | 8.0 ± 2.0 | >0.05 |
| Qp/Qs (mean ± SD) | 1.4 ± 0.2 | 1.3 ± 0.2 | >0.05 |
| AVT (P/N) | 10/28 | 6/16 | >0.05 |
| Targeted therapy (Y/N) | 34/4 | 20/2 | >0.05 |
PAH, pulmonary arterial hypertension; CHD, congenital heart disease; VSD, ventricular septal defect; ASD, atrial septal defect; MAP, mean arterial pressure; mPAP, mean pulmonary arterial pressure; PVRi, pulmonary vascular resistance index; Qp, pulmonary blood flow; Qs, systemic blood flow; AVT, acute vasoreactivity testing; P, positive; N, negative.